7 medtech stories we missed this week: Sept. 22, 2017
[Image from unsplash.com]From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, clinic and directly to patients without a prescription. The MediClear PreOp is a breathable, transparent, self-adhesive, silicone barrier film-drape that can conform to a patient’s skin at a planned incision or insertion site. The film-drape helps protect the patient from bacteria, yeast and viruses. It can be applied by the patient or by clinicians at a consultation prior to surgical procedures. It is then removed immediately before surgery by a clinician in the operating room under sterile conditions. 2. ManaMed launches PlasmaFlow deep vein thrombosis prevention system ManaMed has launched the first FDA-approved digital and tubeless deep vein thrombosis prevention device, according to a Sept. 21 press release. The deep vein thrombosis prevention device, known as PlasmaFlow, is now available to medical practitioners in the U.S. PlasmaFlow is portable and tubeless with multiple pressure functions. It features a one-button operation, soft cuffs made of a high-grade medical material, 10 hours of rechargeable battery life and two LCD screen with a timer and pressure. I...
CONCLUSIONS: Only 25.1% of patients in our study achieved good INR control, despite regular INR monitoring. There is an urgent need to improve anticoagulation control of patients receiving warfarin in SA. Validated dosing algorithms are required, and access to lower warfarin dosage formulations may optimise individual dose titration. Advocacy for these formulations is advised. PMID: 30004329 [PubMed - in process]
Conclusions: The AAA patients undergoing endovascular aneurysm repair showed relatively low short-term mortality. However, larger groups of patients with ruptured AAA are required in order to assess the outcomes in this sub-population. PMID: 30002758 [PubMed]
Conclusions: In the Polish setting, in selected patients, management of high- and intermediate-risk pulmonary embolism with PMPT is technically feasible. Such treatment is relatively safe and effective. It can be an alternative to standard management, especially in patients with contraindications for fibrinolysis or surgical embolectomy. PMID: 30002757 [PubMed]
This study sought to compare the effects of proximal femoral nail anti-rotation (PFNA) and dynamic hip screw (DHS) helical blade treatments in patients with osteoporotic femoral intertrochanteric fractures. PATIENTS AND METHODS: Eighty elderly osteoporosis patients with femoral intertrochanteric fracture complications admitted to the hospital between January 2013 and December 2014 were selected and divided into control (n=40) and observation (n=40) groups. The control group received DHS internal fixation while the observation group received PFNA treatment. Patients were followed up for 18 months, during which pre- and ...
The detection of intraprosthetic thrombus (IPT) deposits is a common finding during follow-up for endovascular abdominal aneurysm repair (EVAR); however, its clinical significance is still debated. The aim of this study was to determine if IPT represents a risk factor for thromboembolic events (TE; endograft or limb thrombosis, or distal embolization) after EVAR.
Anticoagulant induced renal injury has been previously described with Warfarin treatment.In the last decade direct oral anticoagulants (DOAC) were introduced. They include direct inhibitors of factor Xa (Rivaroxaban, Apixaban, Edoxaban) and a thrombin inhibitor (Dabigatran). There are isolated reports describing acute kidney injury (AKI) due to the use of DOACs.
In this issue of Thrombosis Research, Puskarich and colleagues provide new and intriguing insights into the intricate connection of platelet-derived microparticles and their parent cell, the platelet. Using plasma samples from a well-phenotyped cohort of prospectively studied septic patients recruited for a prior clinical trial, these investigators identify an association between sepsis-associated mortality and lower platelet-derived microparticle numbers. They further show that this relationship is driven primarily by sepsis-associated thrombocytopenia.
Heparin Induced Thrombocytopenia (HIT) is a potentially life-threatening disorder caused by antibodies directed against complex of heparin and platelets factor-4 (PF-4) . HIT occurs in 1 in 5000 hospitalized patients and 1 –3% of patients after cardiac surgery, with the incidence being highest with the use of unfractionated heparin . Hospitalized patients can develop thrombocytopenia due to a variety of causes and determining HIT as the cause of thrombocytopenia is crucial because of potential of thrombotic compl ications which affects 50% of the patients .
Since Maureen Andrew began systematically describing thrombosis in children in 1994, there has been surprisingly slow process in advancing our knowledge in terms of diagnosis, prevention and treatment of thrombosis in children. There are a variety of reasons for this slow progress. Overwhelmingly the low incidence of thrombosis in children has been a major barrier. Second, the developmental, age related, changes in haemostasis mean that the physiology of haemostasis in children, and the interaction of the haemostatic system with anticoagulant drugs is constantly changing.
More News: Angioplasty | Austria Health | Baloon Angioplasty | Belgium Health | Carotid Angioplasty | France Health | Germany Health | Hospitals | Laboratory Medicine | Medical Devices | Men | Nanotechnology | Netherlands Health | PET Scan | Portugal Health | Skin | Spain Health | Study | Thrombosis | Ultrasound